Fredun Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 11, 2025, 8:02 pm

Competitors of Fredun Pharmaceuticals Ltd

All Competitor Stocks of Fredun Pharmaceuticals Ltd

Quarterly Result

Last Updated: August 19, 2025, 3:29 pm

Below is a detailed analysis of the quarterly data for Fredun Pharmaceuticals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 119.85 Cr.. The value appears to be declining and may need further review. It has decreased from 167.41 Cr. (Mar 2025) to 119.85 Cr., marking a decrease of 47.56 Cr..
• For Expenses, as of Jun 2025, the value is 102.86 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 149.97 Cr. (Mar 2025) to 102.86 Cr., marking a decrease of 47.11 Cr..
• For Operating Profit, as of Jun 2025, the value is 16.99 Cr.. The value appears to be declining and may need further review. It has decreased from 17.44 Cr. (Mar 2025) to 16.99 Cr., marking a decrease of 0.45 Cr..
• For OPM %, as of Jun 2025, the value is 14.18%. The value appears strong and on an upward trend. It has increased from 10.42% (Mar 2025) to 14.18%, marking an increase of 3.76%.
• For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
• For Interest, as of Jun 2025, the value is 6.53 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 8.15 Cr. (Mar 2025) to 6.53 Cr., marking a decrease of 1.62 Cr..
• For Depreciation, as of Jun 2025, the value is 1.42 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.25 Cr. (Mar 2025) to 1.42 Cr., marking an increase of 0.17 Cr..
• For Profit before tax, as of Jun 2025, the value is 9.04 Cr.. The value appears strong and on an upward trend. It has increased from 8.04 Cr. (Mar 2025) to 9.04 Cr., marking an increase of 1.00 Cr..
• For Tax %, as of Jun 2025, the value is 25.11%. The value appears to be increasing, which may not be favorable. It has increased from 12.06% (Mar 2025) to 25.11%, marking an increase of 13.05%.
• For Net Profit, as of Jun 2025, the value is 6.77 Cr.. The value appears to be declining and may need further review. It has decreased from 7.07 Cr. (Mar 2025) to 6.77 Cr., marking a decrease of 0.30 Cr..
• For EPS in Rs, as of Jun 2025, the value is 14.34. The value appears to be declining and may need further review. It has decreased from 14.97 (Mar 2025) to 14.34, marking a decrease of 0.63.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 3:20 am

Growth

Last Updated: September 5, 2025, 3:30 pm

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Fredun Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 44.83. This value is within the healthy range. It has increased from 33.66 (Mar 24) to 44.83, marking an increase of 11.17.
• For Diluted EPS (Rs.), as of Mar 25, the value is 44.83. This value is within the healthy range. It has increased from 33.32 (Mar 24) to 44.83, marking an increase of 11.51.
• For Cash EPS (Rs.), as of Mar 25, the value is 53.49. This value is within the healthy range. It has increased from 41.32 (Mar 24) to 53.49, marking an increase of 12.17.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 299.47. It has increased from 258.49 (Mar 24) to 299.47, marking an increase of 40.98.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 299.47. It has increased from 258.49 (Mar 24) to 299.47, marking an increase of 40.98.
• For Dividend / Share (Rs.), as of Mar 25, the value is 0.70. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.70.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 956.66. It has increased from 740.88 (Mar 24) to 956.66, marking an increase of 215.78.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 116.69. This value is within the healthy range. It has increased from 82.78 (Mar 24) to 116.69, marking an increase of 33.91.
• For PBIT / Share (Rs.), as of Mar 25, the value is 107.27. This value is within the healthy range. It has increased from 74.70 (Mar 24) to 107.27, marking an increase of 32.57.
• For PBT / Share (Rs.), as of Mar 25, the value is 59.87. This value is within the healthy range. It has increased from 45.65 (Mar 24) to 59.87, marking an increase of 14.22.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 44.07. This value is within the healthy range. It has increased from 33.25 (Mar 24) to 44.07, marking an increase of 10.82.
• For PBDIT Margin (%), as of Mar 25, the value is 12.19. This value is within the healthy range. It has increased from 11.17 (Mar 24) to 12.19, marking an increase of 1.02.
• For PBIT Margin (%), as of Mar 25, the value is 11.21. This value is within the healthy range. It has increased from 10.08 (Mar 24) to 11.21, marking an increase of 1.13.
• For PBT Margin (%), as of Mar 25, the value is 6.25. This value is below the healthy minimum of 10. It has increased from 6.16 (Mar 24) to 6.25, marking an increase of 0.09.
• For Net Profit Margin (%), as of Mar 25, the value is 4.60. This value is below the healthy minimum of 5. It has increased from 4.48 (Mar 24) to 4.60, marking an increase of 0.12.
• For Return on Networth / Equity (%), as of Mar 25, the value is 14.71. This value is below the healthy minimum of 15. It has increased from 12.86 (Mar 24) to 14.71, marking an increase of 1.85.
• For Return on Capital Employeed (%), as of Mar 25, the value is 31.78. This value is within the healthy range. It has increased from 24.93 (Mar 24) to 31.78, marking an increase of 6.85.
• For Return On Assets (%), as of Mar 25, the value is 4.27. This value is below the healthy minimum of 5. It has decreased from 5.07 (Mar 24) to 4.27, marking a decrease of 0.80.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 0.2. It has decreased from 0.10 (Mar 24) to 0.06, marking a decrease of 0.04.
• For Total Debt / Equity (X), as of Mar 25, the value is 1.18. This value exceeds the healthy maximum of 1. It has increased from 0.86 (Mar 24) to 1.18, marking an increase of 0.32.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.14. It has decreased from 1.23 (Mar 24) to 1.14, marking a decrease of 0.09.
• For Current Ratio (X), as of Mar 25, the value is 1.31. This value is below the healthy minimum of 1.5. It has decreased from 1.54 (Mar 24) to 1.31, marking a decrease of 0.23.
• For Quick Ratio (X), as of Mar 25, the value is 0.57. This value is below the healthy minimum of 1. It has increased from 0.49 (Mar 24) to 0.57, marking an increase of 0.08.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.56. This value is below the healthy minimum of 4. It has decreased from 1.75 (Mar 24) to 1.56, marking a decrease of 0.19.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 2.09 (Mar 24) to 0.00, marking a decrease of 2.09.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 1.68 (Mar 24) to 0.00, marking a decrease of 1.68.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 97.91 (Mar 24) to 0.00, marking a decrease of 97.91.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 98.32 (Mar 24) to 0.00, marking a decrease of 98.32.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 2.46. This value is below the healthy minimum of 3. It has decreased from 2.85 (Mar 24) to 2.46, marking a decrease of 0.39.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.93. This value is below the healthy minimum of 3. It has decreased from 2.14 (Mar 24) to 1.93, marking a decrease of 0.21.
• For Enterprise Value (Cr.), as of Mar 25, the value is 477.26. It has increased from 441.23 (Mar 24) to 477.26, marking an increase of 36.03.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.06. This value is within the healthy range. It has decreased from 1.27 (Mar 24) to 1.06, marking a decrease of 0.21.
• For EV / EBITDA (X), as of Mar 25, the value is 8.66. This value is within the healthy range. It has decreased from 11.34 (Mar 24) to 8.66, marking a decrease of 2.68.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.69. This value is below the healthy minimum of 1. It has decreased from 0.96 (Mar 24) to 0.69, marking a decrease of 0.27.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 97.90 (Mar 24) to 0.00, marking a decrease of 97.90.
• For Price / BV (X), as of Mar 25, the value is 2.23. This value is within the healthy range. It has decreased from 2.77 (Mar 24) to 2.23, marking a decrease of 0.54.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.69. This value is below the healthy minimum of 1. It has decreased from 0.96 (Mar 24) to 0.69, marking a decrease of 0.27.
• For EarningsYield, as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has increased from 0.04 (Mar 24) to 0.06, marking an increase of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness